Agios Q2 Revenue Triples on AQVESME Launch; Sickle Cell PDUFA Set for Nov 1
AGIO sits 42% above its 52-week low of $22.24.
Summary
Agios reported Q2 2026 product revenue of $44.7M, up 259% year-over-year, fueled by the AQVESME launch. The FDA set a November 1, 2026 PDUFA date for mitapivat in sickle cell disease.
Key Events · Earnings and Guidance · AGIO
-
Revenue Triples on AQVESME Launch
Product revenue for Q2 2026 reached $44.7M, up from $12.5M in Q2 2025, driven by the U.S. launch of AQVESME for thalassemia and increased PYRUKYND sales.
-
Sickle Cell PDUFA Date Set
The FDA accepted the mitapivat sNDA for sickle cell disease with priority review and set a PDUFA goal date of November 1, 2026.
-
Cash Runway at $1.0B
Cash, cash equivalents, and marketable securities totaled $1.0 billion as of June 30, 2026, expected to fund operations through the potential sickle cell launch.
-
R&D Spend Jumps on Cevidoplenib Deal
R&D expense rose to $100.8M, including a $25M upfront payment to Oscotec for the global license to cevidoplenib, a SYK inhibitor for ITP.
Analysis · AGIO · Life Sciences
Driven by the U.S. launch of AQVESME for thalassemia, Agios' Q2 product revenue surged to $44.7 million—more than triple the prior-year period. The net loss widened to $100.7 million as R&D spending jumped, including a $25 million upfront payment for the cevidoplenib license. The company ended the quarter with $1.0 billion in cash and marketable securities, providing runway to fund operations and prepare for a potential mitapivat launch in sickle cell disease, where an FDA decision is expected by November 1, 2026. Three senior officers also adopted 10b5-1 trading plans covering up to 195,132 shares, a routine but notable disclosure.
At the time of this filing, AGIO was trading at $31.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.